We could not find any results for:
Make sure your spelling is correct or try broadening your search.
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch...
GENFIT fait un point d’actualité sur ses activités à l’occasion de sa participation prochaine à l’AASLD Liver Meeting® 2024 Programme PBC (sous licence Ipsen) : Ipsen présentera de nouvelles...
GENFIT Reports Third Quarter 2024 Financial Information Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended September 30...
GENFIT : Information financière du troisième trimestre 2024 Trésorerie et équivalents de trésorerie s’élevant à 96,0 millions d’euros au 30 septembre 202459,7 millions d’euros de revenus des neuf...
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval Lille (France), Cambridge...
GENFIT : Iqirvo® d’Ipsen (elafibranor) reçoit l’approbation UE en tant que traitement first-in-class de la Cholangite Biliaire Primitive consécutivement à l’approbation accélérée de la FDA...
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone...
GENFIT : Résultats financiers du premier semestre 2024 et point sur les activités de la Société Trésorerie et équivalents de trésorerie s’élevant à 61,6 millions d’euros au 30 juin 2024 n’incluant...
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July...
GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive Lille (France), Cambridge (Massachusetts...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1 | 2.86123032904 | 3.495 | 3.59 | 3.495 | 440 | 3.545 | DE |
4 | -0.095 | -2.57452574526 | 3.69 | 3.73 | 3.415 | 795 | 3.54550915 | DE |
12 | -1.795 | -33.3024118738 | 5.39 | 5.77 | 3.415 | 975 | 4.52628818 | DE |
26 | -0.135 | -3.61930294906 | 3.73 | 5.77 | 3.415 | 1264 | 4.41685471 | DE |
52 | -0.225 | -5.89005235602 | 3.82 | 5.77 | 3.06 | 1405 | 4.26713183 | DE |
156 | 0.09 | 2.56776034237 | 3.505 | 5.77 | 2.855 | 1410 | 4.02964341 | DE |
260 | 0.09 | 2.56776034237 | 3.505 | 5.77 | 2.855 | 1410 | 4.02964341 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions